133 related articles for article (PubMed ID: 36933759)
41. Genetic polymorphism at
Bashash M; Connors JM; Gascoyne RD; Meissner B; Schuetz JM; Leach S; Slack GW; Berry BR; Hu H; Sehn LH; Brooks-Wilson AR; Spinelli JJ
Haematologica; 2017 May; 102(5):e199-e202. PubMed ID: 28154089
[No Abstract] [Full Text] [Related]
42. Primary Lymphoma of Liver-a Rare Space-Occupying Lesion.
Patkar S; Dutt K; Shah A; Sengar M; Goel M
J Gastrointest Cancer; 2020 Sep; 51(3):1057-1060. PubMed ID: 32333249
[No Abstract] [Full Text] [Related]
43. Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms.
Albitar M; Zhang H; Goy A; Xu-Monette ZY; Bhagat G; Visco C; Tzankov A; Fang X; Zhu F; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; Hagemeister FB; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; van Krieken JH; Piris MA; Winter JN; Li Y; Xu B; Young KH
Blood Cancer J; 2022 Feb; 12(2):25. PubMed ID: 35105854
[TBL] [Abstract][Full Text] [Related]
44. Impact of relative dose intensity of standard regimens on survival in elderly patients aged 80 years and older with diffuse large B-cell lymphoma.
Lee S; Fujita K; Negoro E; Morishita T; Oiwa K; Tsukasaki H; Kinoshita K; Kawai Y; Ueda T; Yamauchi T
Haematologica; 2020 Aug; 105(8):e415-e418. PubMed ID: 31919079
[No Abstract] [Full Text] [Related]
45. Novel prognostic index based on hemoglobin level and platelet count for diffuse large B-cell lymphoma, not otherwise specified in the R-CHOP era.
Nakayama S; Matsuda M; Adachi T; Sueda S; Ohashi Y; Awaji S; Hashimoto S; Matsumura I
Platelets; 2019; 30(5):637-645. PubMed ID: 30047815
[TBL] [Abstract][Full Text] [Related]
46. MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphoma.
Due H; Schönherz AA; Ryø L; Primo MN; Jespersen DS; Thomsen EA; Roug AS; Xiao M; Tan X; Pang Y; Young KH; Bøgsted M; Mikkelsen JG; Dybkær K
Blood Adv; 2019 Apr; 3(7):1185-1196. PubMed ID: 30967394
[TBL] [Abstract][Full Text] [Related]
47. The average relative dose intensity of R-CHOP is an independent factor determining favorable overall survival in diffuse large B-cell lymphoma patients.
Długosz-Danecka M; Szmit S; Ogórka T; Skotnicki AB; Jurczak W
Cancer Med; 2019 Mar; 8(3):1103-1109. PubMed ID: 30740919
[TBL] [Abstract][Full Text] [Related]
48. Tiny transformed diffuse large B cell lymphoma localized to the left conjunctiva.
Harada N; Tagami M; Koh H; Ohsawa M; Hino M; Nakamae H
Int J Hematol; 2021 Oct; 114(4):413-414. PubMed ID: 34424492
[No Abstract] [Full Text] [Related]
49. Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era.
Watanabe R; Tomita N; Itabashi M; Ishibashi D; Yamamoto E; Koyama S; Miyashita K; Takahashi H; Nakajima Y; Hattori Y; Motohashi K; Takasaki H; Ohshima R; Hashimoto C; Yamazaki E; Fujimaki K; Sakai R; Fujisawa S; Motomura S; Ishigatsubo Y
Eur J Haematol; 2014 Mar; 92(3):204-10. PubMed ID: 24283206
[TBL] [Abstract][Full Text] [Related]
50. Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study.
Lugtenburg P; Avivi I; Berenschot H; Ilhan O; Marolleau JP; Nagler A; Rueda A; Tani M; Turgut M; Osborne S; Smith R; Pfreundschuh M
Haematologica; 2017 Nov; 102(11):1913-1922. PubMed ID: 28935843
[TBL] [Abstract][Full Text] [Related]
51. Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era.
Kridel R; Telio D; Villa D; Sehn LH; Gerrie AS; Shenkier T; Klasa R; Slack GW; Tan K; Gascoyne RD; Connors JM; Savage KJ
Br J Haematol; 2017 Jan; 176(2):210-221. PubMed ID: 27739058
[TBL] [Abstract][Full Text] [Related]
52. [Current status and future prospects of diffuse large B-cell lymphoma treatment].
Yamaguchi M
Rinsho Ketsueki; 2022; 63(9):1126-1134. PubMed ID: 36198538
[TBL] [Abstract][Full Text] [Related]
53. Early detection of patients with poor risk diffuse large B-cell lymphoma.
Sehn LH
Leuk Lymphoma; 2009 Nov; 50(11):1744-7. PubMed ID: 19860615
[TBL] [Abstract][Full Text] [Related]
54. Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi.
Chiappella A; Tucci A; Castellino A; Pavone V; Baldi I; Carella AM; Orsucci L; Zanni M; Salvi F; Liberati AM; Gaidano G; Bottelli C; Rossini B; Perticone S; De Masi P; Ladetto M; Ciccone G; Palumbo A; Rossi G; Vitolo U;
Haematologica; 2013 Nov; 98(11):1732-8. PubMed ID: 23812930
[TBL] [Abstract][Full Text] [Related]
55. Chidamide combined with ibrutinib improved the prognosis of primary bone marrow diffuse large B cell lymphoma.
Tian C; Chen Z; Li Y
J Int Med Res; 2020 Jul; 48(7):300060520936053. PubMed ID: 32643971
[TBL] [Abstract][Full Text] [Related]
56. [Therapeutic developments and advances in B-cell lymphoma].
Miyazaki K
Rinsho Ketsueki; 2022; 63(6):619-625. PubMed ID: 35831197
[TBL] [Abstract][Full Text] [Related]
57. The Clinical and Hormonal Characteristics of Primary Adrenal Lymphomas: The Necessity of Early Detection of Adrenal Insufficiency.
Harada K; Kimura K; Iwamuro M; Terasaka T; Hanayama Y; Kondo E; Hayashi E; Yoshino T; Otsuka F
Intern Med; 2017 Sep; 56(17):2261-2269. PubMed ID: 28794358
[TBL] [Abstract][Full Text] [Related]
58. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
Poeschel V; Held G; Ziepert M; Witzens-Harig M; Holte H; Thurner L; Borchmann P; Viardot A; Soekler M; Keller U; Schmidt C; Truemper L; Mahlberg R; Marks R; Hoeffkes HG; Metzner B; Dierlamm J; Frickhofen N; Haenel M; Neubauer A; Kneba M; Merli F; Tucci A; de Nully Brown P; Federico M; Lengfelder E; di Rocco A; Trappe R; Rosenwald A; Berdel C; Maisenhoelder M; Shpilberg O; Amam J; Christofyllakis K; Hartmann F; Murawski N; Stilgenbauer S; Nickelsen M; Wulf G; Glass B; Schmitz N; Altmann B; Loeffler M; Pfreundschuh M; ;
Lancet; 2019 Dec; 394(10216):2271-2281. PubMed ID: 31868632
[TBL] [Abstract][Full Text] [Related]
59. Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL).
Jung SH; Lee JJ; Kim WS; Lee WS; Do YR; Oh SY; Kim MK; Mun YC; Shin HJ; Kwak JY; Kang HJ; Won JH; Kwon JH; Park E; Suh C; Yang DH
Eur J Haematol; 2015 Jun; 94(6):504-10. PubMed ID: 25288018
[TBL] [Abstract][Full Text] [Related]
60. Management of elderly patients with malignant lymphoma.
Miyazaki K
Jpn J Clin Oncol; 2022 Jul; 52(7):690-699. PubMed ID: 35435235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
